Monday, August 31, 2026

Moderna Stock Bullish Momentum With A 3.56% Rise Today

ViaNews Editorial Team

December 23, 2020

Moderna Stock Bullish Momentum With A 3.56% Rise Today

The Nasdaq Stock Market ended the session with Moderna rising 3.56% to $130.36 on Wednesday while the Nasdaq Stock Market rose 0.05% to $12,813.90.

Moderna today's close was $130.36, 36.93% under its 52-week high of $178.50.

News about Moderna today

Health Canada authorizes Moderna Covid-19 vaccine. According to today's article on Business Insider, "Health Canada received Moderna's submission on October 12, 2020, and after a thorough, independent review of the evidence, it has determined that the Moderna vaccine meets the Department's stringent safety, efficacy and quality requirements.", "The terms and conditions of the Moderna vaccine authorization require the manufacturer to continue providing information to Health Canada on the safety, efficacy and quality of the vaccine to ensure the benefits of the vaccine continue to be demonstrated through market use."

Moderna shot gets approval in Canada’s expanding vaccine effort. According to today's article on Bloomberg Quint, "Canada's public health authorities approved Moderna Inc.'s coronavirus vaccine, the second shot to be licensed in a country that's secured more doses per person than any other around the world.", ""The different storage and handling requirements of the Moderna Covid-19 vaccine mean that it can be distributed to isolated and remote communities, including the territories.""

Canada authorizes Moderna vaccine. According to today's article on MarketWatch, "Shares of Moderna Inc. were down 0.1% in trading on Wednesday after it said Canada authorized its COVID-19 vaccine for adults. "

Moderna's Sales

Moderna's sales growth is 1841.7% for the ongoing quarter and 19117.5% for the next. The company's growth estimates for the ongoing quarter is a negative 2.7% and positive 660% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Yearly Top and Bottom Value

Moderna's stock is valued at $130.36 at 16:12 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's worth is way higher than its 50-day moving average of $118.15 and way higher than its 200-day moving average of $81.36.

Previous days news about Moderna

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company's coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

Moderna, biontech post worst day for vaccine stocks in a month. According to Bloomberg Quint on Tue Dec 22, "Tuesday's slide puts a small dent in a rally that has pushed Moderna's shares to jump more than sixfold so far this year while BioNTech has nearly tripled in value.", "Moderna, BioNTech and Pfizer have each traded off their highs since their vaccines received regulatory clearance."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com